Micafungin in the treatment of invasive candidiasis and invasive aspergillosis

Nathan P Wiederhold1, Jason M Cota2, Christopher R Frei11University of Texas at Austin College of Pharmacy, Austin, Texas, USA; 2University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas, USAAbstract: Micafungin is an echinocandin antifungal agent available for clinical use in Jap...

Full description

Bibliographic Details
Main Authors: Nathan P Wiederhold, Jason M Cota, Christopher R Frei
Format: Article
Language:English
Published: Dove Medical Press 2009-01-01
Series:Infection and Drug Resistance
Online Access:http://www.dovepress.com/micafungin-in-the-treatment-of-invasive-candidiasis-and-invasive-asper-a2784
id doaj-55f7053ecbe94b5c93a90bb95a912582
record_format Article
spelling doaj-55f7053ecbe94b5c93a90bb95a9125822020-11-24T21:00:36ZengDove Medical PressInfection and Drug Resistance1178-69732009-01-012008default6377Micafungin in the treatment of invasive candidiasis and invasive aspergillosisNathan P WiederholdJason M CotaChristopher R FreiNathan P Wiederhold1, Jason M Cota2, Christopher R Frei11University of Texas at Austin College of Pharmacy, Austin, Texas, USA; 2University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas, USAAbstract: Micafungin is an echinocandin antifungal agent available for clinical use in Japan, Europe, and the United States. Through inhibition of β-1,3-glucan production, an essential component of the fungal cell wall, micafungin exhibits potent antifungal activity against key pathogenic fungi, including Candida and Aspergillus species, while contributing minimal toxicity to mammalian cells. This activity is maintained against polyene and azole-resistant isolates. Pharmacokinetic and pharmacodynamic studies have demonstrated linear kinetics both in adults and children with concentration-dependent activity observed both in vitro and in vivo. Dosage escalation studies have also demonstrated that doses much higher than those currently recommended may be administered without serious adverse effects. Clinically, micafungin has been shown to be efficacious for the treatment of invasive candidiasis and invasive aspergillosis. Furthermore, the clinical effectiveness of micafungin against these infections occurs without the drug interactions that occur with the azoles and the nephrotoxicity observed with amphotericin B formulations. This review will focus on the pharmacology, clinical microbiology, mechanisms of resistance, safety, and clinical efficacy of micafungin in the treatment of invasive candidiasis and invasive aspergillosis.Keywords: micafungin, echinocandin, Candida, Aspergillus, invasive candidiasis, invasive aspergillosis http://www.dovepress.com/micafungin-in-the-treatment-of-invasive-candidiasis-and-invasive-asper-a2784
collection DOAJ
language English
format Article
sources DOAJ
author Nathan P Wiederhold
Jason M Cota
Christopher R Frei
spellingShingle Nathan P Wiederhold
Jason M Cota
Christopher R Frei
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
Infection and Drug Resistance
author_facet Nathan P Wiederhold
Jason M Cota
Christopher R Frei
author_sort Nathan P Wiederhold
title Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
title_short Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
title_full Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
title_fullStr Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
title_full_unstemmed Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
title_sort micafungin in the treatment of invasive candidiasis and invasive aspergillosis
publisher Dove Medical Press
series Infection and Drug Resistance
issn 1178-6973
publishDate 2009-01-01
description Nathan P Wiederhold1, Jason M Cota2, Christopher R Frei11University of Texas at Austin College of Pharmacy, Austin, Texas, USA; 2University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas, USAAbstract: Micafungin is an echinocandin antifungal agent available for clinical use in Japan, Europe, and the United States. Through inhibition of β-1,3-glucan production, an essential component of the fungal cell wall, micafungin exhibits potent antifungal activity against key pathogenic fungi, including Candida and Aspergillus species, while contributing minimal toxicity to mammalian cells. This activity is maintained against polyene and azole-resistant isolates. Pharmacokinetic and pharmacodynamic studies have demonstrated linear kinetics both in adults and children with concentration-dependent activity observed both in vitro and in vivo. Dosage escalation studies have also demonstrated that doses much higher than those currently recommended may be administered without serious adverse effects. Clinically, micafungin has been shown to be efficacious for the treatment of invasive candidiasis and invasive aspergillosis. Furthermore, the clinical effectiveness of micafungin against these infections occurs without the drug interactions that occur with the azoles and the nephrotoxicity observed with amphotericin B formulations. This review will focus on the pharmacology, clinical microbiology, mechanisms of resistance, safety, and clinical efficacy of micafungin in the treatment of invasive candidiasis and invasive aspergillosis.Keywords: micafungin, echinocandin, Candida, Aspergillus, invasive candidiasis, invasive aspergillosis
url http://www.dovepress.com/micafungin-in-the-treatment-of-invasive-candidiasis-and-invasive-asper-a2784
work_keys_str_mv AT nathanpwiederhold micafungininthetreatmentofinvasivecandidiasisandinvasiveaspergillosis
AT jasonmcota micafungininthetreatmentofinvasivecandidiasisandinvasiveaspergillosis
AT christopherrfrei micafungininthetreatmentofinvasivecandidiasisandinvasiveaspergillosis
_version_ 1716779213374095360